Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The few therapeutic strategies for advance hepatocellular carcinoma (HCC) on poor knowledge of its biology. For several years, sorafenib, a tyrosine kinase inhibitors (TKI) inhibitor, has been the approved treatment option, to date, for advanced HCC patients. Its activity is the inhibition of the retrovirus-associated DNA sequences protein (RAS)/Rapidly Accelerated Fibrosarcoma protein (RAF)/mitogen-activated and extracellular-signal regulated kinase (MEK)/extracellular-signal regulated kinases (ERK) signaling pathway. However, the efficacy of sorafenib is limited by the development of drug resistance, and the major neuronal isoform of RAF, BRAF and MEK pathways play a critical and central role in HCC escape from TKIs activity. Advanced HCC patients with a BRAF mutation display a multifocal and/or more aggressive behavior with resistance to TKI. Moreover, also long non-coding RNA (lnc-RNA) have been studied in epigenetic studies for BRAF aggressiveness in HCC. So far, lnc-RNA of BRAF could be another mechanism of cancer proliferation and TKI escape in HCC and the inhibition could become a possible strategy treatment for HCC. Moreover, recent preclinical studies and clinical trials evidence that combined treatments, involving alternative pathways, have an important role of therapy for HCC and they could bypass resistance to the following TKIs: MEK, ERKs/ribosomal protein S6 kinase 2 (RSK2), and phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR). These initial data must be confirmed in clinical studies, which are currently ongoing. Translational research discoveries could create new strategies of targeted therapy combinations, including BRAF pathway, and they could eventually bring light in new treatment of HCC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
- Date Crossref
- 21/11/2019
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
San Gallicano Hospital pays non établi dans la noticeÉtablissement de santé
-
Istituto Tumori Bari pays non établi dans la noticeÉtablissement de santé
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
University of Bari Aldo Moro pays non établi dans la noticeUniversité ou école supérieure
-
“S. Cuore di Gesù” Hospital Medical Oncology Unit pays non établi dans la noticeÉtablissement de santé
-
Policlinico di Bari Department of Surgery and Liver Transplantation pays non établi dans la noticeÉtablissement de santé
-
National Cancer Research Centre Medical Oncology Unit pays non établi dans la noticeStructure de recherche
-
University of Bari Medical School Department of Biomedical Sciences and Human Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Medical Thoracic Oncology Unit pays non établi dans la noticeInstitution
San Gallicano Hospital, Istituto Tumori Bari et Istituti di Ricovero e Cura a Carattere Scientifico, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.